NCT07632092 Early [18F]-FDG PET Dynamic Analysis in Brain Metastases After Radiotherapy.
| NCT ID | NCT07632092 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Short Time Examination |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-05-18 |
| Primary Completion | 2028-11-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-05-18 with a primary completion date of 2028-11-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Various treatment options are available for brain metastases, depending on factors such as lesion site or number lesions. Radiotherapy is a commonly used treatment. Following stereotactic radiotherapy for brain metastases, a potential complication, namely brain radionecrosis, can occur subsequently. It is essential to differentiate between this radionecrosis and lesion recurrence in order to determine the appropriate treatment approach. Contrast-enhanced magnetic resonance imaging (MRI) is the most widely used technique for monitoring brain metastases. Therefore, patients undergo routine MRI at 3 months and during subsequent follow-ups, but if the lesion evolve and if distinguishing between recurrence and radionecrosis is challenging, an \[18F\]-FDG PET scan is then prescribed by oncologists or radiotherapists during follow-up consultations. As part of the standard patient management protocol, a 10-minute image acquisition begins after a 45-60 minutes wait following the radiotracer injection. A second image acquisition is then conducted 3-4 hours later. For both acquisitions, a low-dose X-ray scanner is synchronously coupled to allow attenuation correction of the PET images. Patient for whom a \[18F\]-FDG PET cerebral examination has been prescribed as part of the usual management of brain metastases will be eligible to the protocol. If the patient agrees to participate, an early imaging session is initiated immediately upon radiotracer injection, lasting 15 minutes in addition to the standard acquisition protocol.
Eligibility Criteria
Inclusion Criteria: * Patient referred for cerebral \[18F\]-FDG PET examination prescribed as part of his usual medical care for brain metastasis. * Age ≥ 18 years old * Affiliation to a social security program * Ability of the subject to understand and express his consent Exclusion Criteria: * Age under 18 years old * Person under guardianship or curatorship * Pregnant or breastfeeding woman * Primary brain tumors * Brain metastases from renal, thyroid or other cancers known to have low avidity for \[18F\]-FDG
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07632092 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Short Time Examination. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07632092 currently recruiting?
Yes, NCT07632092 is actively recruiting participants. Contact the research team at Girard.Antoine@chu-amiens.fr for enrollment information.
Where is the NCT07632092 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT07632092 clinical trial?
NCT07632092 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 50 participants.